Taiwan News1h
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, and MURA-7012, targeted split sub-units of IL-12; Mural anticipates an IND ...
Important Milestone for Biotest: Biologics License Application for Fibrinogen Submitted to the US Food and Drug Administration (FDA)
Biotest's Fibrinogen Aims to Fulfill a High Unmet Medical Need for Additional Fibrinogen to Treat Acquired Fibrinogen Deficiency US Submission Follows EU Application for Marketing Authorization ...
The Pharma Letter5h
Grifols files fibrinogen BLA
Spanish firm Grifols has submitted a Biologics License Application (BLA) for its new potential fibrinogen treatment to the US ...
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...
PipelineReview.com5h
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
The FDA and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and ...
Healio6h
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor
A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...
The FDA Continues to Intimidate Doctors and Defraud the American Public
HOUSTON, TEXAS / ACCESSWIRE / January 9, 2025 / The Golden Gift announced today that affordable plasma interventions can have significant health and economic benefits to prevent or manage age-related ...
Lost Money on Sangamo Therapeutics, Inc. (SGMO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...
Johnson & Johnson: Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...
J&J gets Priority Review designation for nipocalimab BLA
Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...
Johnson & Johnson reports nipocalimab granted FDA Priority Review
Johnson & Johnson announced the nipocalimab Biologics License Application received Priority Review designation from the U.S Food and Drug ...
EQS-News: Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)
Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...